Objectives To compare prices of new drugs between France and the other EU4. Methods Study used IMS MIDAS database for economic data such as prices and sales volume and LEEM database (French association of the pharmaceutical manufacturers) for the ASMR scale (HAS assessment of the drug’s added...

Study Design. Multicentric, randomized, and controlled study of clinical evaluation of medical device in subacute low back pain. Objective. To evaluate the effects of an elastic lumbar belt on functional capacity, pain intensity in low back pain treatment, and the benefice on medical cost....

Objectives Policy makers pay more and more attention to the orphan drug market. Pharmaceutical companies are suspected to take advantage of the legislation. Moreover, granted an orphan designation (OD) could be associated with higher prices. The aim of this work is to assess the impact of the...

This thesis aims to undertake an economic analysis of private medical practice while stressing on elements, which in our view, remain unsaid or unrecognised. It is about an institutional analysis, based on the historic and social embedding of the health. After presenting the specificities of...

Price regulation and competition patterns in the ethical drug industry in france This article gives the results of an econometric modelization of the ethical drugs price and quantity determination institutionnal process for France. From price and promotion elasticities, it is shown that...

Le texte ci-dessous entend contribuer à enrichir le débat sur une des principales innovations qui aient été proposées ces dernières années pour le système de santé. Ce débat doit porter sur la pertinence du constat préalable, sur la logique du projet des Réseaux de Soins Coordonnés...

After generics, which are copies of chemical medicines, "copies" of already patented biologics (biosimilars) are entering the biologics market and competing with their originators. Many uncertainties remain regarding the development of this newly emerging market, and the ability of biosimilars...